By the Oregon Health and Science University
Scientists from the Oregon Health and Science University are using 3-D technology to actually view serotonin transporters in the brain. This research can lead to better treatments for anxiety, mood disorders, and depression.
Visualizing this molecular structure creates a platform for designing new, more effective small molecule therapeutics to treat depression and anxiety.
“The heavy toll that devastating illnesses like anxiety and depression have on families and communities is, in many ways, incalculable. Revealing the precise structure of the serotonin transporter holds tremendous promise for the development of life-changing drug treatments for these diseases,” said Eric Gouaux, Ph.D., senior scientist in the Vollum Institute at OHSU, National Academy of Sciences member, and Howard Hughes Medical Institute Investigator. Gouaux is an internationally recognized crystallographers in the area of neurotransmitter receptor and transporter structure.
Influencing virtually all human behaviors, serotonin regulates the activity of the central nervous system as well as processes throughout the body, from cardiovascular function to digestion, body temperature, endocrinology and reproduction. The serotonin transporter acts as a molecular pump for serotonin, recycling the neurotransmitter following neuronal signaling. Serotonin shapes neurological processes including sleep, mood, cognition, pain, hunger and aggression.
When SSRIs were first developed in the 1980s, the molecular identity of the transporter they targeted was unknown. In the 1990s, researchers realized that SSRIs had a common target — the serotonin transporter. By binding to the transporter and blocking serotonin from being taken back up by the transporter into the cell, SSRIs allow serotonin to remain outside of the cell longer than normal, potentially prolonging neuronal signaling. Though SSRIs are widely used to treat anxiety and depression, the molecular mechanism by which they block the transporter is not fully understood.
Gouaux’s lab used X-ray crystallography to capture images of the transporter. In this paper, they report that SSRIs lock the transporter in an outward-open conformation by loading in the central binding site, directly blocking serotonin binding.
The study, “X-ray structures and mechanism of the human serotonin transporter,” was authored by Gouaux; Jonathan A. Coleman, Ph.D.; and Evan M. Green, a research assistant who is now a Ph.D. student at University of California San Francisco.
Oregon Health & Science University. (2016, April 6). Researchers visualize brain’s serotonin pump, provide blueprint for new, more effective SSRIs: Revealing serotonin transporter’s molecular structure opens new era of drug treatments for depression and anxiety. ScienceDaily. Retrieved April 20, 2016 from www.sciencedaily.com/releases/2016/04/160406140336.htm
Related Continuing Education Courses
Professional Development Resources, Inc. is a Florida nonprofit educational corporation 501(c)(3) that offers 150+ online, video and book-based continuing education courses for healthcare professionals. We are approved by the American Psychological Association (APA); the National Board of Certified Counselors (NBCC); the Association of Social Work Boards (ASWB); the American Occupational Therapy Association (AOTA); the American Speech-Language-Hearing Association (ASHA); the Commission on Dietetic Registration (b); the Alabama State Board of Occupational Therapy; the Florida Boards of Social Work, Mental Health Counseling and Marriage and Family Therapy, Psychology & School Psychology, Dietetics & Nutrition, Speech-Language Pathology and Audiology, and Occupational Therapy Practice; the Ohio Counselor, Social Worker & MFT Board and Board of Speech-Language Pathology and Audiology; the South Carolina Board of Professional Counselors & MFTs; and by the Texas Board of Examiners of Marriage & Family Therapists and State Board of Social Worker Examiners. |